Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines

Biologicals

Volumn 39, Issue 4, 2011, Pages 236-241

  Jiménez Alberto, Alicia ^a   Parreiras, Patricia ^a   Castelán Vega, Juan ^a   Sirota, Lev ^a   Arciniega, Juan ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Anthrax; Anti PA ELISA; AVA; Potency test; RPA

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TEMPERATURE SENSITIVITY;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; MICE;

ANIMALIA; MUS;

EID: 79961207928     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.05.001     Document Type: Article

References (39)

1. Groseclose S.L., Knowles C.M., Hall P.A., Adams D.A., Anderson W.J., Snavely K., et al. Summary of notifiable diseases - United States 1998. MMWR 1999, 47:1-93.
2. McNabb S.J.N., Jajosky R.A., Hall-Baker P.A., Adams D.A., Sharp P., Worshams C., et al. Summary of notifiable diseases - United States 2006. MMWR 2008, 55:1-92.
3. Santelli E., Bankston L.A., Leppla S.H., Liddington R.C. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004, 430:905-908.
4. Liu S., Leung H.J., Leppla S.H. Characterization of the interaction between anthrax toxin and its cellular receptors. Cell Microbiol 2007, 9:977-987.
5. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280:734-737.
6. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 1982, 79:3162-3166.
7. Young J.A.T., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007, 76:243-265.
8. Little S.F., Ivins B.E., Webster W.M., Norris S.L.W., Andrews G.P. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007, 25:2771-2777.
9. Huang J., Mikszta J.A., Ferriter M.S., Jiang G., Harvey N.G., Dyas B., et al. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin 2007, 3:90-93.
10. Campbell J.D., Clement K.H.L., Wasserman S.S., Donegan S., Chrisley L., Kotloff K.L. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007, 3:205-211.
11. Tournier J., Ulrich R.G., Quesnel-Hellmann A., Mohamadzadeh M., Stiles B.G. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther 2009, 7:219-236.
12. WHO Working group meeting on standardization of acellular pertussis vaccines: potency assay: Beijing, China, 7-9 November 2007. Vaccine 2008, 26:3960-3968.
13. Hendriksen C.F.M. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev Vaccines 2009, 8:313-322.
14. Arciniega J.L., Corbel M., Dellepiane N., Dobbelaer R., Griffiths E., Heron I., et al. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. Biologicals 1998, 26:195-204.
15. Little S.F., Webster W.M., Ivins B.E., Fellows P.F., Norris S.L., Andrews G.P. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine 2008, 22:2843-2852.
16. Pombo M., Berthold I., Gingrich E., Jaramillo M., Leef M., Sirota L., et al. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Biologicals 2004, 32:157-163.
17. Hering D., Thompson W., Hewetson J., Little S., Norris S., Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals 2004, 32:17-27.
18. Omland K.S., Brys A., Lansky D., Clement K., Lynn F. Participating laboratories, interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin Vaccine Immunol 2008, 15:946-953.
19. Li H., Soroka S.D., Taylor T.H., Stamey K.L., Stinson K.W., Freeman A.E., et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008, 333:89-106.
20. Powell B.S., Enama J.T., Ribot W.J., Webster W., Little S., Hoover T., et al. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins 2007, 68:458-479.
21. Zomber G., Reuveny S., Garti N., Shafferman A., Elhanany E. Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J Biol Chem 2005, 280:39897-39906.
22. Radha C., Salotra P., Bhat R., Bhatnagar R. Thermostabilization of protective antigen - the binding component of anthrax lethal toxin. J Biotechnol 1996, 50:235-242.
23. Singh S., Singh A., Aziz M.A., Waheed S.M., Bhat R., Bhatnagar R. Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes. Biochem Biophys Res Commun 2004, 322:1029-1037.
24. Chalton D.A., Kelly I.F., McGregor A., Ridley H., Watkinson A., Miller J., et al. Unfolding transitions of Bacillus anthracis protective antigen. Arch Biochem Biophys 2007, 465:1-10.
25. Jiang G., Joshi S.B., Peek L.J., Brandau D.T., Huang J., Ferriter M.S., et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006, 95:80-96.
26. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001, 69:2888-2893.
27. Castelán-Vega J., Corvette L., Sirota L., Arciniega J.L. Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay. Clin Vaccine Immunol 2011, 18:349-351.
28. Berthold I., Pombo M., Wagner L., Arciniega J.L. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005, 23:1993-1999.
29. Reizenstein E., Hallander H.O., Blackwelder W.C., Kühn I., Ljungman M., Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995, 183:279-290.
30. Little S.F., Webster W.M., Wilhelm H., Powell B., Enama J., Adamovicz J.J. Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice. Biologicals 2008, 36:287-295.
31. Parreiras P.M., Sirota L.A., Wagner L.D., Menzies S.L., Arciniega J.L. Comparability of ELISA and toxin neutralization to measure immunogenicity of protective antigen in mice as part of a potency test for anthrax vaccines. Vaccine 2009, 27:4537-4542.
32. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2004, 13:825-840.
33. Puziss M., Wright G.G. Studies on immunity in anthrax X gel-adsorbed protective antigen for immunization of man. J Bacteriol 1963, 85:230-236.
34. Rait V.K., Xu L., O'Leary T.J., Mason J.T. Modeling formalin fixation and antigen retrieval with bovine pancreatic RNase A II. Interrelationship of cross-linking, immunoreactivity, and heat treatment. Lab Invest 2004, 84:300-306.
35. Mason J.T., O'Leary T.J. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem 1991, 39:225-229.
36. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004, 22:422-430.
37. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001, 19:4768-4773.
38. Kobiler D., Gozes Y., Rosenberg H., Marcus D., Reuveny S., Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 2002, 70:544-560.
39. Thalen M., van der Ark A., van den Ijssel J., van Straaten I., Jansen D., Beuvery C., et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 2008, 26:653-663.